IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
4.365
-0.855 (-16.38%)
At close: Jun 5, 2026, 4:00 PM EDT
4.158
-0.207 (-4.75%)
After-hours: Jun 5, 2026, 7:44 PM EDT
IceCure Medical Employees
As of December 31, 2025, IceCure Medical had 69 total employees, including 67 full-time and 2 part-time employees. The number of employees increased by 3 or 4.55% compared to the previous year.
Employees
69
Change (1Y)
3
Growth (1Y)
4.55%
Revenue / Employee
$51,667
Profits / Employee
-$228,159
Market Cap
11.81M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69 | 3 | 4.55% | 67 | 2 |
| Dec 31, 2024 | 66 | -11 | -14.29% | 64 | 2 |
| Dec 31, 2023 | 77 | 5 | 6.94% | 71 | 6 |
| Dec 31, 2022 | 72 | 8 | 12.50% | 65 | 7 |
| Dec 31, 2021 | 64 | 17 | 36.17% | 55 | 9 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Trinity Biotech | 287 |
| Vivos Therapeutics | 270 |
| IRIDEX | 93 |
| Lifeward | 81 |
| VolitionRx | 75 |
| Adagio Medical Holdings | 41 |
| enVVeno Medical | 33 |
| Sintx Technologies | 32 |
ICCM News
- 2 days ago - Icecure Medical Ltd trading halted, news pending - TheFly
- 4 days ago - IceCure Medical implements 1-for-30 reverse share split for Nasdaq compliance - TheFly
- 4 days ago - IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance - PRNewsWire
- 18 days ago - IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked - PRNewsWire
- 23 days ago - IceCure Medical price target lowered to $1 from $3 at Maxim - TheFly
- 24 days ago - IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - PRNewsWire
- 25 days ago - IceCure Medical reports Q1 EPS (6c) vs. (6c) last year - TheFly
- 25 days ago - IceCure Medical Earnings Call Transcript: Q1 2026 - Transcripts